Shots:

• The P-III DAPA-CKD trial involves assessing of Farxiga (10mg) + SOC vs PBO in 4.304 patients with CKD stages 2-4 and elevated urinary albumin excretion- with/ out T2D 
• Results: 39% reduction in worsening of renal function or risk of CV or renal death- ARR (5.3%) @2.4yrs.- met its 2EPs with 31% reduction in death- safety and tolerability were consistent- AEs (29.5% vs 33.9%)
• Farxiga (PO- qd) is an SGLT2 inhibitor indicated in adults for the treatment of insufficiently controlled T2D as both monothx. and combination therapy as an adjunct to diet and exercise to improve glycemic control- weight loss and BP reduction

­ Ref: AstraZeneca | Image: FX Empire